Managing Partner – Value Creation — Quality And Supply Network

The mandate

An advisory partnership is planning succession in its value-creation practice as pharmaceutical boards increasingly seek economic improvement during quality-system remediation. Clients need cost, throughput and working-capital change, but benefit claims can become dangerous if they pressure investigation, release or compliance. The replacement Managing Partner will build a method that treats control recovery as the foundation of value.

Approximately 1,000 employees and material partners sit across quality, supply, operations, technical, data, finance and transformation advisory. The Managing Partner reports to the Global Managing Partner and regional partner council, owning proposition, origination, engagement risk, economics, delivery and partner development. The Copenhagen hybrid advisory appointment remains categorised as CONTRACTOR.

The proposition will begin with control and product flow. Teams should trace material, batch, test, deviation, release and distribution while identifying waiting, rework and failure demand. A generic cost benchmark cannot reveal whether capacity is constrained by equipment, evidence, skill or quality decisions.

Remediation scope must be independently understood. Advisers will review observations, risk, commitments and effectiveness evidence with authorised quality leaders. They may improve programme design and operations, but they cannot negotiate away a required control or declare remediation complete.

Value baselines will separate compliance investment, recurring inefficiency and growth capacity. Avoided harm or inspection risk should not be converted casually into financial return. Cost and cash claims need ledger evidence; capacity benefits require released, usable throughput and demand.

Quality and productivity can improve together when the cause is poor flow. Right-first-time documentation, better material control or faster exception triage may reduce both risk and lead time. The practice will measure balancing outcomes and stop interventions that create premature closure, batching distortion or hidden backlog.

Inventory work needs pharmaceutical context. Safety stock, quarantine, expiry, minimum batches and uncertain yield interact. The Managing Partner will ensure teams model continuity and regulatory constraints before recommending reduction. Inventory released by delaying a needed batch is not value.

External supply is often the largest dependency. Contract manufacturers and laboratories hold evidence, capacity and technical knowledge. Value programmes will include quality agreements, change, scheduling, data and escalation. Commercial leverage cannot be used in a way that discourages deviation reporting or threatens continuity.

Technology enablement should follow controlled work. Digital batch records, planning tools and quality platforms can improve flow, but validation, data integrity and adoption cost must be included. Installation milestones will not count as value. Advisers must show the changed decision or process.

Workforce decisions require capability evidence. Remediation can create temporary teams and consultant dependence, while routine roles remain understaffed. The practice will map authorisation, investigation and technical skill, design transfer and ensure reductions do not remove independent challenge or single-source expertise.

Engagement governance will separate client ownership from adviser delivery. Every initiative needs a functional owner and route into normal management. The Managing Partner will resist permanent programme structures that make advisers indispensable. Effectiveness should be tested after handback.

Sponsors and quality leaders may have different time horizons. The partner must state where an economic target conflicts with remediation evidence, and propose a safer sequence. Independent judgement matters more than pleasing either side. Significant disagreement will be documented for the client board.

The practice itself needs succession. The outgoing leader owns sponsor relationships and a recognised intervention style. The new Managing Partner will share accounts, develop quality-and-supply partners and standardise evidence principles without turning them into a rigid template.

What you will own

• Pharmaceutical quality-and-supply value proposition.
• Sponsor origination and client-board stewardship.
• Remediation-aware diagnostic and benefit methods.
• Flow, inventory, external supply and digital interventions.
• Engagement acceptance, quality and independence.
• Client ownership transfer and outcome verification.
• Account succession and partner development.
• Practice contribution and reputation.

The first 12 months

Within 60 days, review live remediations, benefits and client conflicts; correct any claim unsupported by control or ledger evidence. Agree account transition with the incumbent.

By month six, launch two quality-and-supply interventions, implement independent effectiveness review and place emerging partners in substantive sponsor relationships.

At twelve months, verify DKK 700 million of annualised client value without weakened control, with at least 80% supported by ledger or usable-capacity evidence. Ten priority remediation outcomes should pass effectiveness review, and 75% of inherited accounts should have shared partner ownership. No quality-independence or data-integrity breach is acceptable.

What the council will test

• Control recovery preceding economic claims.
• Flow diagnostics tracing real batch work.
• Inventory advice protecting continuity and expiry.
• Supplier leverage preserving quality reporting.
• Workforce changes retaining authorised capability.
• Client leaders operating benefits after adviser exit.

The person

You bring 28+ years in pharmaceutical value creation, operations, quality, private equity or senior advisory. Your record includes quality-system remediation and measurable supply-chain or manufacturing value across international networks.

Candidates must show a cost action they rejected because it weakened control and value verified after programme handback. The hybrid Copenhagen role requires frequent client-site presence and international travel.

Compensation and terms

Base compensation is DKK 3,700,000–5,200,000 plus annual incentive and long-term participation linked to verified value, remediation outcomes, independence, clients and partner succession. The hybrid Copenhagen advisory appointment reports to the Global Managing Partner and regional partner council. Planned replacement permits orderly account transition.

Confidentiality

The partnership, clients, sponsors, products, quality findings, suppliers, benefits and succession plans remain confidential. Further material follows conflicts and signed confidentiality. Applicants must not contact pharmaceutical companies or advisers to infer the client.